First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients

NCT06531447 Phase 2 ACTIVE_NOT_RECRUITING

The goal of the study is to investigate of the prognostics and predictive role of TUBB3 expression in locally advanced breast cancer

Details

Lead sponsor	The National Center of Oncology, Azerbaijan
Phase	Phase 2
Status	ACTIVE_NOT_RECRUITING
Enrolment	200
Start date	2014-05
Completion	2027-05

Conditions

• Breast Cancer

Interventions

• Cisplatin
• Gemcitabine
• Doxorubicin
• Cyclophosphamide
• Paclitaxel

Primary outcomes

• Clinical tumor regression rate — 4 months
  Chemotherapy combination Gemcitabine with Cisplatin

Countries

Azerbaijan